Adcetris Drug Interactions

CYP3A4 Inhibitors, Inducers and Substrates: Co-administration of Adcetris with ketoconazole, a strong CYP3A4 inhibitor and P-gp inhibitor, did not alter exposure to Adcetris; however, a moderate increase to the exposure to MMAE was observed. Patients who are receiving strong CYP3A4 inhibitors and P-gp inhibitors concomitantly with Adcetris should be closely monitored for adverse events.
Co-administration of Adcetris with rifampicin, a strong CYP3A4 inducer, did not alter exposure to Adcetris; however, a moderate reduction to the exposure to MMAE was observed. Co-administration of Adcetris with CYP3A4 inducers is not expected to have an impact on safety or efficacy.
Co-administration of midazolam, a CYP3A4 substrate, with Adcetris did not alter the metabolism of midazolam; therefore Adcetris is not expected to alter the exposure to drugs that are metabolized by CYP3A4 enzymes (See Pharmacology: Pharmacokinetics under Actions).
Doxorubicin, Vinblastine and Dacarbazine: The serum and plasma pharmacokinetic characteristics of ADC and MMAE respectively following administration of Adcetris in combination with doxorubicin, vinblastine and dacarbazine were similar to that in monotherapy.
Co-administration of Adcetris did not affect the plasma exposure of doxorubicin, vinblastine or dacarbazine.
Cyclophosphamide, Doxorubicin, and Prednisone: The serum and plasma pharmacokinetic characteristics of ADC and MMAE, respectively, following administration of Adcetris in combination with cyclophosphamide, doxorubicin, and prednisone were similar to that in monotherapy.